Netherlands Clinical Trials Management System Market Size & Outlook
Netherlands clinical trials management system market, 2017-2030 (US$M)
Related Markets
Netherlands clinical trials management system market highlights
- The Netherlands clinical trials management system market generated a revenue of USD 32.8 million in 2023 and is expected to reach USD 80.9 million by 2030.
- The Netherlands market is expected to grow at a CAGR of 13.8% from 2024 to 2030.
- In terms of segment, web & cloud based was the largest revenue generating delivery mode in 2023.
- Web & Cloud based is the most lucrative delivery mode segment registering the fastest growth during the forecast period.
Clinical trials management system market data book summary
| Market revenue in 2023 | USD 32.8 million |
| Market revenue in 2030 | USD 80.9 million |
| Growth rate | 13.8% (CAGR from 2023 to 2030) |
| Largest segment | Web & cloud based |
| Fastest growing segment | Web & Cloud based |
| Historical data | 2017 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Web & Cloud based, On premise |
| Key market players worldwide | IQVIA Holdings Inc, Medidata, Oracle Corp, DATATRAK International Inc, Clario, PAREXEL, Labcorp Holdings Inc, Veeva Systems Inc Class A, Wipro Ltd ADR |
Other key industry trends
- In terms of revenue, Netherlands accounted for 1.8% of the global clinical trials management system market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany clinical trials management system market is projected to lead the regional market in terms of revenue in 2030.
- Netherlands is the fastest growing regional market in Europe and is projected to reach USD 80.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Clinical Trials Management System Market Scope
Clinical Trials Management System Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Netherlands clinical trials management system market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical trials management system market will help companies and investors design strategic landscapes.
Web & cloud based was the largest segment with a revenue share of 70.73% in 2023. Horizon Databook has segmented the Netherlands clinical trials management system market based on web & cloud based, on premise covering the revenue growth of each sub-segment from 2017 to 2030.
The Netherlands is the only European country to consistently hold the top position in the Euro Health Consumer Index. Healthcare expenditure in this country is higher than in several other OECD countries, such as Italy, the UK, France, Denmark, and Sweden.
The increasing incidence of chronic diseases in the country is expected to propel the number of clinical research activities being conducted, creating market opportunities for CTMS providers in the coming years.
According to a study published in 2020 by Health Action International, the majority of Dutch healthcare companies and research institutions lack transparency in clinical trials, which can potentially harm patients.
Reasons to subscribe to Netherlands clinical trials management system market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Netherlands clinical trials management system market databook
-
Our clientele includes a mix of clinical trials management system market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Netherlands clinical trials management system market , including forecasts for subscribers. This country databook contains high-level insights into Netherlands clinical trials management system market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Netherlands clinical trials management system market size, by delivery mode, 2017-2030 (US$M)
Netherlands Clinical Trials Management System Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
